Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) have been given a consensus rating of “Hold” by the six research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to […]
StockNews.com upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) from a sell rating to a hold rating in a research report sent to investors on Friday. Separately, JPMorgan Chase & Co. lowered their price target on Enanta Pharmaceuticals from $12.00 to $11.00 and set an underweight rating on the stock in a report on […]
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Hold" from Analysts theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) CFO Paul J. Mellett sold 2,412 shares of the firm’s stock in a transaction dated Tuesday, December 5th. The stock was sold at an average price of $9.63, for a total value of $23,227.56. Following the sale, the chief financial officer now directly owns 93,549 shares in […]
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) VP Brendan Luu sold 2,125 shares of the stock in a transaction that occurred on Tuesday, December 5th. The stock was sold at an average price of $9.63, for a total value of $20,463.75. Following the sale, the vice president now directly owns 36,736 shares in the […]